AMGN•prnewswire•
Dark Blue Therapeutics acquired by Amgen for up to $840 million
Summary
Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings a new therapeutic mechanism to Amgen's extensive cancer portfolio – Dark Blue has pioneered the biology of targeting MLLT1/3, and DBT...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 6, 2026 by prnewswire